GlobeNewswire

ADC Therapeutics Doses First Patient in Pivotal Clinical Trial of ADCT-402 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Del

Phase II trial evaluating efficacy and safety of CD19-targeting antibody drug conjugate intended to support submission of Biologics License Application

Top-line data expected in third quarter of 2019

LAUSANNE, Switzerland, Aug. 07, 2018 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase II clinical trial intended to support the submission of Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). The clinical trial is evaluating the efficacy and safety of ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

At the 2017 American Society of Hematology (ASH) Annual Meeting, the Company presented interim Phase I data on ADCT-402 in 138 evaluable, heavily pre-treated lymphoma patients who had failed, or were intolerant to, any established therapy known to provide clinical benefit, with a median of three prior therapies. At the time, for the 49 response-evaluable patients in Part 1 of the study (dose escalation) with DLBCL who received ADCT-402 at doses greater than or equal to 120 μg/kg, the overall response rate (ORR) was 55 percent (27/49), with 18 patients achieving a complete response (37 percent) and 9 patients achieving a partial response (18 percent).

The primary endpoint of the Phase II, multi-center, open-label, single-arm trial is the ORR in patients treated with ADCT-402, as confirmed by central review. Secondary endpoints include assessments of duration of response, complete response rate, relapse-free survival, progression-free survival and overall survival, as well as safety, pharmacokinetics and health-related quality of life. The trial will enroll approximately 140 patients with relapsed or refractory DLBCL at multiple centers in the USA and Europe.

“We are pleased to have dosed the first patient in our registrational Phase II clinical trial evaluating ADCT-402 in patients with DLBCL who have relapsed and have refractory disease after two or more multi-agent treatment regimens. Our Phase I clinical trial of ADCT-402 in non-Hodgkin lymphoma showed significant activity in patients with DLBCL and an acceptable safety profile,” said Jay Feingold, MD, PhD, Chief Medical Officer and Senior Vice President of Clinical Development at ADC Therapeutics. “Unfortunately, there is no effective treatment for patients with multiple relapsed and refractory DLBCL, so we are excited about the potential to improve outcomes in these patients with ADCT-402 in a single-arm trial. We anticipate reporting results from the Phase II trial in the third quarter of 2019 and are hopeful that the data will support our submission of a BLA to the FDA.”

Alex Spira, MD, PhD, FACP, Director of Virginia Cancer Specialists Research Institute and Clinical Assistant Professor of Oncology at Johns Hopkins School of Medicine, added, “Patients with DLBCL who have relapsed or are refractory after second-line chemotherapy face a very poor prognosis. There is a significant unmet need for an effective new treatment option for this patient population, and we believe ADCT-402 has the potential to help impact patient outcomes in this disease.”

For more information about the Phase II clinical trial, please visit www.clinicaltrials.gov (identifier NCT03589469).

ADC Therapeutics also plans to initiate multiple combination studies with ADCT-402 in the fourth quarter of 2018.

About Diffuse Large B-Cell Lymphoma (DLBCL)

Non-Hodgkin lymphoma (NHL) is the seventh most common type of cancer in the U.S., and accounted for an estimated 4.3 percent of new cancer cases in 2017.1 Diffuse large B-cell lymphoma (DLBCL) accounts for nearly one-third (32.5 percent) of NHL.2 The most common initial treatment for patients with DLBCL is chemo-immunotherapy. Response to initial treatment is high, but more than half of patients do not have long-term disease control.3 The current standard of care for relapsed DLBCL is additional chemotherapy, which can be followed by stem cell transplantation (SCT). The prognosis for relapsed patients is poor, especially for those with chemotherapy-refractory disease with a short interval between remission and relapse or those who relapse after high-dose therapy and SCT. There is a significant unmet need for an effective treatment for patients with relapsed or refractory DLBCL.

About ADCT-402

ADCT-402 is an antibody drug conjugate (ADC) composed of a humanized monoclonal antibody that binds to human CD19, conjugated through a linker to a pyrrolobenzodiazepine (PBD) dimer toxin. Once bound to a CD19-expressing cell, ADCT-402 is internalized into the cell where enzymes release the PBD-based warhead. CD19 is a clinically validated target for the treatment of B-cell malignancies. The PBD-based warhead has the ability to form highly cytotoxic DNA interstrand cross-links, blocking cell division and resulting in cell death. Preliminary data from a Phase I clinical trial in relapsed or refractory B-cell non-Hodgkin lymphoma demonstrate ADCT-402 has significant activity in patients with diffuse large B-cell lymphoma (DLBCL). ADCT-402 is also being evaluated in an ongoing Phase I clinical trial in patients with relapsed or refractory B-cell lineage acute lymphoblastic leukemia (B-ALL). The U.S. Food and Drug Administration has granted orphan drug designation to ADCT-402 for the treatment of DLBCL and mantle cell lymphoma.

About ADC Therapeutics

ADC Therapeutics SA is an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs) targeting major hematological malignancies and solid tumors. The Company’s ADCs are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads via a chemical linker. The Company has multiple PBD-based ADCs in ongoing clinical trials in the USA and Europe, and a deep pipeline of other preclinical ADCs in development. ADC Therapeutics has world-class partners, including AstraZeneca and its global biologics research and development arm, MedImmune. The Company is based in Lausanne (Biopôle), Switzerland and has operations in London, San Francisco and New Jersey. For more information, visit www.adctherapeutics.com.

1 Siegel et al., 2017
2 Al-Hamadani et al., 2015
3 Gisselbrecht et al., 2010

               
Investors Contact      EU Media Contact     USA Media Contact  
Dr. Chris Martin     Alexandre Müller     Tony Plohoros  
Chief Executive Officer     Dynamics Group     6 Degrees  
Chris.martin@adctherapeutics.com     amu@dynamicsgroup.ch     tplohoros@6degreespr.com  
Tel.: +41 (0) 21 653 0200     Tel: +41 (0) 43 268 3231     Tel.: +1 908-591-2839  

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

ERYTECH Announces Immune Modulation Strategic Collaboration with SQZ Biotechnologies24.6.2019 23:30:00 CESTPressemelding

LYON, France and CAMBRIDGE, Mass., June 24, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (ERYTECH) (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells (RBCs), announced today that it has entered into an agreement with SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments in multiple therapeutic areas, to advance novel RBC-based therapeutics for immune modulation . Under the terms of the agreement, ERYTECH has granted to SQZ an exclusive worldwide license to develop antigen-specific immune modulating therapies employing RBC-based approaches. Combining SQZ’s proprietary and versatile cell engineering platform, Cell Squeeze®, with ERYTECH’s intellectual property related to RBC-based therapeutics is intended to allow for the rapid development of a broad pipeline of novel immunomodulatory products addressing multiple indications. ERYTECH is eligible to rec

Forterra Announces Leadership Appointments24.6.2019 22:24:00 CESTPressemelding

Construction Materials Veteran Karl H. Watson, Jr. Named Chief Executive Officer Forterra Board Member John McPherson Appointed Lead Director and Vice Chairman of the Board Company Reaffirms Full Year 2019 Outlook IRVING, Texas, June 24, 2019 (GLOBE NEWSWIRE) -- Forterra, Inc. (“Forterra” or the “Company”) (NASDAQ:FRTA), a leading manufacturer of water and drainage infrastructure pipe and products in the United States and Eastern Canada, today announced that Karl H. Watson, Jr. has been appointed Chief Executive Officer and a member of the Forterra Board of Directors. Mr. Watson succeeds Jeff Bradley, who has stepped down as CEO and a director to pursue other opportunities. Mr. Watson brings over 30 years of global experience in the construction materials industry and a track record of effectively leading through numerous business cycles and improving financial and operational results. He most recently served as Executive Vice President and Chief Operating Officer at Summit Materials,

Oxford Immunotec Appoints Patrick J. Balthrop, Sr. as Chairman24.6.2019 17:35:00 CESTPressemelding

OXFORD, United Kingdom and MARLBOROUGH, Mass., June 24, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it has appointed Patrick J. Balthrop, Sr. as Chairman of its board of directors. The current Chairman, Mr. Richard A. Sandberg, will remain a member of the board. “On behalf of the Company and the board of directors I would like to thank our former Chairman, Richard Sandberg, for his service,” said Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec. “In the decade that he served as Chairman, the Company has undergone a profound transformation, and Mr. Sandberg’s guidance and leadership has made an extraordinary contribution to Oxford Immunotec’s success. We look forward to continuing to benefit from his skills and his knowledge of the Company with his ongoing service as a Non-Executive Director.” “We are very pleased to have Mr. Balthrop assume the role of Chairman,” continued Dr. Wrigh

Woodbridge by Robert Mondavi Announces New Transformative Brand Positioning24.6.2019 15:50:00 CESTPressemelding

“From One For All” National Campaign Brings Brand’s Pioneering Spirit to the Forefront of Story and Marks a Number of Brand Firsts LODI, Calif., June 24, 2019 (GLOBE NEWSWIRE) -- Woodbridge by Robert Mondavi, the number-three wine brand in the United States* with 40 years of history dedicated to raising the standard for everyday wines in America and globally, announces a new milestone with the launch of its new national brand campaign. The “From One For All” campaign celebrates Woodbridge founder Robert Mondavi’s pivotal role in democratizing wine. It is supported by a 360-degree integrated marketing plan backed by the largest investment in the brand’s history. For the first time, Woodbridge by Robert Mondavi tells the winery’s powerful founding story and industry-changing vision through the lens of its iconic founder Robert Mondavi in the new “From One For All” marketing campaign. Celebrated for his achievements helping to establish California’s reputation for fine winemaking on a glo

Sanan IC Expands Wafer Foundry Portfolio for Power Electronics with 150mm GaN-on-Silicon Process24.6.2019 15:00:00 CESTPressemelding

SUNNYVALE, Calif., June 24, 2019 (GLOBE NEWSWIRE) -- SANAN INTEGRATED CIRCUIT CO., LTD. (Sanan IC), a pure-play wafer foundry with its advanced compound semiconductor technology platform, today announced the commercial release of its 150mm gallium nitride (GaN) on silicon wafer foundry services intended for the latest high voltage AC/DC and DC/AC power electronics applications in the global market. Sanan IC’s new G06P111 is a 650V enhanced-mode high-electron-mobility transistor (E-HEMT) GaN process which adds to the company’s power electronics wafer foundry portfolio of wide bandgap (WBG) compound semiconductors that includes 100mm and 150mm silicon carbide (SiC) for high voltage Schottky Barrier Diodes (SBD). Leveraging years of high volume GaN manufacturing experience by Sanan Optoelectronics Inc., its parent company, for the LED market, Sanan IC is able to complement its foundry services with in-house MOCVD growth capabilities of high voltage, low leakage GaN-on-silicon epitaxial wa

Nasdaq Promotes Tal Cohen to Executive Vice President, North American Market Services24.6.2019 14:30:00 CESTPressemelding

Tom Wittman to become Executive Advisor and to retire from Nasdaq at year-end NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Nasdaq, Inc. today announced it has named Tal Cohen as Executive Vice President, North American Market Services, effective July 1. In this role, Cohen will be responsible for driving the strategy and success of our trading businesses across cash equities, commodities, derivatives, and trade management services in Nasdaq’s U.S. and Canadian markets. In his role, in addition to directing the strategy of the business, Cohen will oversee Nasdaq’s North American trading products across their lifecycle and will manage client relationships and market operations. He will report to Adena Friedman, President and CEO, Nasdaq. Cohen joined Nasdaq in April 2016 as Senior Vice President of North American Equities following the acquisition of Chi-X Canada, where he had served as CEO of Chi-X Global Holdings for six years. Prior to Chi-X, Cohen held senior positions at Instinet, Am